Alcon Buys Rights For Durezol and Zirgan
Alcon has bought rights for and Zirgan from Sirion Therapeutics Inc. for an undisclosed amount. While Durezol is an ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, Zirgan is an antiviral for the treatment of corneal ulcers. Both products have been approved by the Food and Drug Administration.
Alcon said it has acquired the global rights, excluding Latin America, for Zyclorin, which is being developed as a potential treatment for dry eyes and other diseases.
- Alcon To Purchase Ophthalmic Pharmaceutical Assets From Sirion
- Data from comparative trial involving Durezol and Pred Forte
- FDA grants Durezol priority review status
- CHMP recommends Azarga for approval
